Medtronic, Inc. Release: Recent Studies Suggest Benefits of Continuous Glucose Monitoring

MINNEAPOLIS--(BUSINESS WIRE)--In acknowledgement of this year’s World Diabetes Day, which calls on all those responsible for diabetes care to understand diabetes and take control, Medtronic, Inc. (NYSE: MDT) highlights the growing body of clinical evidence for Personal Continuous Glucose Monitoring (CGM) in improving glucose control for diabetes patients.

MORE ON THIS TOPIC